Stable, Above Historical Average Influenza Activity due to Novel Pandemic H1N1 in BC

MSP
Influenza illness as a proportion of all submitted BC Medical Services Plan (MSP) claims were at levels consistent with the historical median in week 34. On a regional level VIHA maintained an elevated proportion and NHA a reduced proportion of claims related to ILI compared to previous years (See graphs, pages 4-6.)

ILI Outbreaks
No influenza outbreaks were reported in schools or facilities during week 34. Since April 20, when public health partners were first informed of the evolving situation in Mexico, specimens have been submitted to BCCDC Laboratory Services in relation to 36 ILI outbreak investigations (25 in LTCFs, 4 in schools, 2 in ACFs, 2 in correctional facilities, 2 in summer camps, and 1 in a workplace). Influenza A/H3N2 was identified in 4 of the investigations (all LTCFs), nH1N1 was identified in 4 (two summer camps, one school, one correctional facility), influenza B in 1 school, rhino/enterovirus in 3 LTCFs, HMPV in 2 LTCFs, and coronavirus in a workplace. No pathogen was identified in the other 21. (See graph on page 6.)

Please remember to notify BCCDC of any ILI outbreaks occurring in your region by sending an e-mail to ilioutbreak@bccdc.ca and attaching the outbreak report form (a copy is found at the end of this report).

Laboratory Reports
BCCDC Laboratory Services tested 289 respiratory specimens in week 34. Three (1%) specimens tested positive for human influenza viruses. 29 (10.0%) tested positive for nH1N1, a decrease compared to previous weeks. Other respiratory pathogens detected included: rhino/enterovirus (6.2% of specimens tested), adenovirus (0.7%) and parainfluenza (1.7%).

During week 33, Children’s and Women’s Health Centre Laboratory tested 42 respiratory specimens. Two tested positive for nH1N1, 1 tested positive for parainfluenza and 1 for adenovirus. Data for week 34 is not yet available (See graphs on page 7).
Novel pandemic H1N1
BCCDC continues to monitor the novel H1N1 virus pandemic. To date, 4 laboratory confirmed cases have died. The age distribution of nH1N1 cases indicates that younger persons are disproportionately affected. An epidemic curve showing BC ambulatory and hospitalized cases as well as a graph showing the age-stratified cumulative case rates are presented on page 8.

For further description of BC nH1N1 cases, visit: www.bccdc.ca/discoond/DiseaseStatsReports/influSurveillanceReports.htm

nH1N1-related information and resources for healthcare professionals are available at: www.bccdc.ca/resourcematerials/newsandalerts/healthalerts /H1N1FluVirusHumanSwineFlu.htm

Antiviral Resistance
Drug susceptibility testing at the NML as of August 31 indicated that most (n=320) human influenza A/H1N1 isolates tested to date were resistant to oseltamivir (one human H1N1 isolate identified since mid-April was sensitive). All human H3N2 (n=194), influenza B (n=573), and nH1N1 (n=527) isolates tested at the NML were found to be sensitive to oseltamivir. Of the isolates tested for amantadine resistance, all (n=319) human H1N1 isolates were found to be sensitive, all (n=396) human H3N2 isolates were found to be resistant, and all (n=361) nH1N1 isolates were found to be sensitive. All 1305 (257 human H1N1, 190 human H3N2, 578 influenza B, and 280 nH1N1) isolates that have been tested for zanamivir resistance were sensitive.

On July 21, Canada reported its first case of oseltamivir resistant nH1N1 (aka: swine flu) in a patient from Quebec who received post-exposure prophylaxis following illness in a family member. Eleven other nH1N1 isolates resistant to oseltamivir (from China, Hong Kong, Singapore, Japan, USA, and Denmark) have been identified in cases and reported to the WHO; there are no epidemiological links between these cases.

In summary, global surveillance has shown that circulating nH1N1 viruses are resistant to amantadine but remain sensitive to zanamivir and oseltamivir, although sporadic cases of oseltamivir resistance have been observed.

FluWatch
During week 34 (Aug 23-22), activity levels were similar to the previous week, but are consistent with a declining trend. Compared to week 33 the proportion of tests positive for influenza and ILI consultation rate remained approximately constant at 3.4 % and 12 per 1000 patient visits respectively. These figures illustrate of a decline from 23% tests positive and 41 per 1000 patient visits in the week ending June 13. Overall activity remains slightly higher than expected for this time of year. www.phac-aspc.gc.ca/fluwatch/

National Microbiology Laboratory
Since Sept 1, 2008 and as of August 31, 1306 influenza isolates from provincial and hospital labs have been characterized at the National Microbiology Laboratory (NML):
262 A/Brisbane/59/07(H1N1)-like* † from BC, AB, SK, MB, ON, QC, NB, NS, & PEI;
172 A/Brisbane/10/07(H3N2)-like* † from all ten provinces;
11 B/Florida/04/06(Yamagata)-like* from AB, ON, QC & NB;
379 B/Malaysia/2506/04(Victoria)-like from all ten provinces;
180 B/ Brisbane/60/08(Victoria)-like ‡ from BC, AB, SK, MB, ON, QC, NB, NS, & NU; and
302 A/California/07/2009-like§ from BC, AB, SK, MB, ON, QC, NB, NS, NT, & NU;
* indicates a strain match to the 2008-09 vaccine
† indicates a strain match to the 2009-10 vaccine
‡ A/California/07/2009 (H1N1) is the variant reference virus (nH1N1) selected by WHO as a potential candidate for a pandemic influenza A/H1N1 vaccine.

INTERNATIONAL
In the United States, in the week ending August 29 (week 34) influenza activity as determined by sentinel physician visits and geographic spread increased. Seventeen percent of respiratory specimens tested in reference laboratories during this week were positive for influenza, representing an overall decrease from the peak of 39% during week ending June 20. Ninety-seven percent of the subtyped influenza A viruses were nH1N1. In Europe for the week ending August 30, influenza activity remains low in most countries, with the exception of Sweden where there is medium, widespread activity with an increasing trend. Above baseline activity has also been reported in Ireland and the UK (Northern Ireland) and Norway but with a decreasing trend. Details are available at: http://www.cdc.gov/flu/weekly/ and http://www.eiss.org .

Several countries in the Southern Hemisphere previously reporting severe winter influenza activity
have now passed the peak. Notably as of August 21st in Australia, most jurisdictions are reporting that nH1N1 activity has either peaked or plateaued and presentations to ERs are decreasing; children under 5 years remain the most frequently hospitalized age group. In New Zealand as of August 30, nH1N1 activity continues to decline; consultations with sentinel physicians have declined to less than half those observed during the peak in early July, but remain elevated compared to previous years. The highest consultation rates are among children less than 5 years, followed by the 5-19 and 20-34 age groups. In Chile as of September 2, a clear downward trend in the number of cases continues from the peak observed in early July; the highest rates are among children aged 5-14 years. In Argentina, for the week ending August 22 there was no change in trend compared to the previous week. Overall the number of confirmed cases also continues to decrease from the peak in late June. Ninety-two percent of circulating respiratory viruses in ages >5 years were nH1N1; among ages 5 years and under the proportion is 23%. In South Africa, laboratories are currently reporting nH1N1 is the dominant influenza subtype; previously, in June and July of this year the dominant subtype was A H3N2. For more information, see:

For information on nH1N1 globally, visit the WHO website at:

Vaccine Composition
The 2008-09 influenza vaccine contained the following virus antigens:
- A/Brisbane/59/2007(H1N1)-like
- A/Brisbane/10/2007(H3N2)-like
Note: A/Uruguay/716/2007(H3N2) is antigenically equivalent to A/Brisbane/10/2007(H3N2) and may be included by vaccine producers.
- B/Florida/04/2006(Yamagata lineage)-like
The WHO has announced the recommended components of the 2009-10 northern hemisphere seasonal influenza vaccine:
- A/Brisbane/59/2007(H1N1)-like
- A/Brisbane/10/2007(H3N2)-like
- B/Brissbane/60/2008(Victoria lineage)-like
Thus, only the B component will be changed from the 2008-09 vaccine. For additional information, visit:

Contact Us:
Epidemiology Services
BC Centre for Disease Control (BCCDC)
655 W. 12th Ave, Vancouver BC V5Z 4R4
Tel: (604) 707-2510 / Fax: (604) 707-2516
InfluenzaFieldEpi@bccdc.ca

List of Acronyms
ACF: Acute Care Facility
AI: Avian Influenza
FHA: Fraser Health Authority
HMPV: Human metapneumovirus
HSDA: Health Service Delivery Area
IHA: Interior Health Authority
ILI: Influenza-Like Illness
LTCF: Long Term Care Facility
MSP: BC Medical Services Plan
NHA: Northern Health Authority
NML: National Microbiological Laboratory
OIE: World Organization for Animal Health
RSV: Respiratory syncytial virus
VCHA: Vancouver Coastal Health Authority
VIHA: Vancouver Island Health Authority
WHO: World Health Organization

Web Sites
1. Influenza Web Sites
Canada – Flu Watch:
http://www.phac-aspc.gc.ca/fluwatch/
NACI Statement on Influenza Vaccination for the 2008-09 Season:
Washington State Flu Updates:
http://www.doh.wa.gov/ehs/phl/epidemiology/CD/HTML/FluUpdate.htm
USA Weekly Surveillance reports:
http://www.cdc.gov/flu/weekly/
European Influenza Surveillance Scheme:
http://www.eiss.org/index.cgi
WHO – Global Influenza Surveillance Scheme:
http://www.eiss.org/index.cgi
WHO – Global Influenza Programme:
http://www.who.int/csr/disease/influenza/mission/
WHO – Weekly Epidemiological Record:
http://www.who.int/wer/en/
Influenza Centre (Australia):
http://www.influenzacentre.org/

2. Avian Influenza Web Sites
World Health Organization – Avian Influenza:
http://www.who.int/csr/disease/avian_influenza/en/
World Organization for Animal Health:
http://www.oie.int/eng/en_index.htm

3. This Report On-line
http://www.bccdc.ca/dis-cond/DiseaseStatsReports/inflSurveillanceReports.htm

4. Swine Influenza Web Sites
BCCDC: http://www.bccdc.ca/dis-cond/a-z/HumanSwineFlu/default.htm
**WEEKLY SENTINEL ILI**

Percentage of Patient Visits due to Influenza Like Illness (ILI) per Week Compared to Average Percentage of ILI Visits for the Past 19 Seasons
Sentinel Physicians, British Columbia, 2008-2009

![Graph showing weekly sentinel ILI percentage](image)

**INFLUENZA ILLNESS CLAIMS* VIA BC MEDICAL SERVICES PLAN (MSP)**
**ENTIRE PROVINCE – CURRENT TO SEPTEMBER 1, 2009**

![Graph showing influenza illness claims](image)

*Influenza illness is tracked as the percentage of all submitted MSP general practitioner claims with ICD-9 code 487 (influenza).

**Note:** MSP week 27 Sep 2008 corresponds to sentinel ILI week 40.
ILI OUTBREAKS

Number of Influenza-Like Illness (ILI) Outbreaks Investigated or Reported, Compared to Current ILI Rate and Average ILI Rate for past 19 years, per Week
British Columbia, 2008-2009

* Influ LTCF = Long-term care facility, influenza identified
* Other LTCF = Long-term care facility, other pathogen identified (including RSV, parainfluenza, adenovirus, and rhino/enterovirus)
* ILI (No Pathogen) LTCF = Long-term care facility, no pathogen identified
**LABORATORY SUMMARY**

**Virus Detections and Percentage of Respiratory Specimens Submitted to BC Provincial Laboratory Diagnosed Positive for Human Influenza and Novel Pandemic H1N1 Virus (nH1N1), per Week, BC, 2008-2009**

*Note:* The increase in bars during weeks 17-19 above reflects the large surge in specimens submitted to BCCDC for testing (2594 specimens were tested, a 5-fold increase over the number of tests performed during the 3-week period of peak activity this season).

**Virus Detections and Percentage of Respiratory Specimens Submitted to Children and Women's Health Centre Laboratory Diagnosed Positive for a Virus, per Week, British Columbia, 2008-2009**

*Note:* Data for the week 34 are not yet available.
nH1N1 – RELATED GRAPHS

Novel Pandemic H1N1*, BC Cases by Collection Date (as of August 31, 2009)
N = 812 (including 42 hospitalized cases)
* formerly known as swine-origin influenza virus

nH1N1 Cumulative Case Rate by Age, per 100,000 Population, BC, April 17 - August 31, 2009
Influenza-Like Illness (ILI) Outbreak Summary Report Form

Please complete and email to ilioutbreak@bccdc.ca or fax to (604) 660-0197

**ILI:** Acute onset of respiratory illness with fever and cough and with one or more of the following: sore throat, arthralgia, myalgia, or prostration which could be due to influenza virus. In children under 5, gastrointestinal symptoms may also be present. In patients under 5 or 65 and older, fever may not be prominent.

**Schools and work site outbreak:** greater than 10% absenteeism on any day, most likely due to ILI.

**Residential institutions (facilities) outbreak:** two or more cases of ILI within a seven-day period.

---

**SECTION A: Reporting Information**

Person Reporting: ______________________ Title: _____________________________

Contact Phone: ______________________ Email: ____________________________

Health Authority: ______________________ HSDA: ____________________________

Full Facility Name: __________________________________________________________

Is this report:  
☐ First Notification (complete section B below; Section D if available)  
☐ Update (complete section C below; Section D if available)  
☐ Outbreak Over (complete section C below; Section D if available)

**SECTION B: First Notification**

Type of facility:  
☐ LTCF  
☐ Acute Care Hospital  
☐ Senior’s Residence  
☐ Workplace  
☐ School (grades:_______)  
☐ Other ( _________)

(if ward or wing, please specify name/number: ______________________)

Date of onset of first case of ILI (dd/mm/yyyy): __________ /_______ / ______

<table>
<thead>
<tr>
<th>Numbers to date</th>
<th>Residents/Students</th>
<th>Staff</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total</td>
<td></td>
<td></td>
</tr>
<tr>
<td>With ILI</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hospitalized</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Died</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

**SECTION C: Update AND Outbreak Declared Over**

Date of onset for most recent case of ILI (dd/mm/yyyy): ______ / _____ / ______

If over, date outbreak declared over (dd/mm/yyyy): ______ / _____ / ______

<table>
<thead>
<tr>
<th>Numbers to date</th>
<th>Residents/Students</th>
<th>Staff</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total</td>
<td></td>
<td></td>
</tr>
<tr>
<td>With ILI</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hospitalized</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Died</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

**SECTION D: Laboratory Information**

Specimen(s) submitted?  
☐ Yes (location: ______________ )  ☐ No  ☐ Don’t know

If yes, organism identified?  
☐ Yes (specify: _______________ )  ☐ No  ☐ Don’t know